Full Text View
Tabular View
No Study Results Posted
Related Studies
Mathematical Modeling Analysis of Serum Prostate Specific Antigen After Radiotherapy
This study is ongoing, but not recruiting participants.
Study NCT00126815   Information provided by Alberta Cancer Board
First Received: August 3, 2005   Last Updated: September 11, 2006   History of Changes

August 3, 2005
September 11, 2006
February 2004
 
 
 
Complete list of historical versions of study NCT00126815 on ClinicalTrials.gov Archive Site
 
 
 
Mathematical Modeling Analysis of Serum Prostate Specific Antigen After Radiotherapy
Mathematical Modeling Analysis of Serum Prostate Specific Antigen After Radiotherapy

Clinical data (prostate-specific antigen [PSA] response after radiotherapy) are being used to build a mathematical model to describe the clinical results of radiotherapy for prostate cancer.

 
 
Observational
Natural History, Cross-Sectional, Defined Population, Retrospective Study
Prostate Cancer
 
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Active, not recruiting
1000
July 2005
 

Inclusion Criteria:

  • Prostate cancer treated with radiotherapy +/- hormones

Exclusion Criteria:

  • Prostatectomy
Male
 
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00126815
 
NA-15-0002
Alberta Cancer Board
 
Principal Investigator: Matthew Parliament, MD Alberta Cancer Board
Alberta Cancer Board
September 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP